In addition, M1NVs in combination with anti‐PD‐L1 Ab therapy significantly improved the ratio of CD8+ T cells/Tregs and reduced tumor progression in CT26 tumor‐bearing mice model. The gene discussed is CD8A; the disease is neoplasm.